Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Startled Venezuelans express relief but also fear after Maduro arrest - 2Understanding Preschool Projects: Cultivating Abilities and Advancement
- 3The 1 question we have to ask ourselves about the Taylor Frankie Paul 'Bachelorette' scandal
- 4Spanish woman, 25, dies by legal euthanasia in case that drew national spotlight
- 5'Zootopia 2' movie reviews: A heartwarming, hysterical and earnest 'ode to community'
- These are the Fastest Italian Sports Cars
- Rachael Ray is navigating grief this holiday season. She doesn't have time for 'negative energy' on the internet.
- Trump declares Christmas Eve and Dec. 26 federal holidays: What does that mean?
- Allow Innovative Progressions To have a Tremendous Effect
- Savvy Cleaning: The 6 Robot Vacuums of 2024
- Vaccine committee votes to scrap universal hepatitis B shots for newborns despite outcry from children’s health experts
- French Senate debates social media ban for under-15s
- Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts
- Former defense minister Gallant vacated home over security threat under Shin Bet direction
